Adverse events of IBD therapies
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 Suppl 2 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 14 Suppl 2(2008) vom: 15. Okt., Seite S210-1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scribano, Maria Lia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Q81I59GXC |
|---|
| Anmerkungen: |
Date Completed 02.12.2009 Date Revised 13.09.2018 published: Print ErratumIn: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ibd.20702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM182662136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM182662136 | ||
| 003 | DE-627 | ||
| 005 | 20231223163242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ibd.20702 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0609.xml |
| 035 | |a (DE-627)NLM182662136 | ||
| 035 | |a (NLM)18816669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scribano, Maria Lia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse events of IBD therapies |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.12.2009 | ||
| 500 | |a Date Revised 13.09.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Mesalamine |2 NLM | |
| 650 | 7 | |a 4Q81I59GXC |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g 14 Suppl 2(2008) vom: 15. Okt., Seite S210-1 |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:14 Suppl 2 |g year:2008 |g day:15 |g month:10 |g pages:S210-1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ibd.20702 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 Suppl 2 |j 2008 |b 15 |c 10 |h S210-1 | ||